Monte Rosa Therapeutics (GLUE) Accounts Payables (2023 - 2025)
Historic Accounts Payables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $17.9 million.
- Monte Rosa Therapeutics' Accounts Payables rose 1856.41% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.9 million, marking a year-over-year increase of 1856.41%. This contributed to the annual value of $18.8 million for FY2024, which is 2866.44% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Accounts Payables of $17.9 million as of Q3 2025, which was up 1856.41% from $13.8 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Accounts Payables registered a high of $18.8 million during Q4 2024, and its lowest value of $10.2 million during Q1 2023.
- Its 3-year average for Accounts Payables is $14.1 million, with a median of $14.2 million in 2023.
- Per our database at Business Quant, Monte Rosa Therapeutics' Accounts Payables skyrocketed by 458.85% in 2024 and then skyrocketed by 5203.02% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Accounts Payables stood at $14.6 million in 2023, then rose by 28.66% to $18.8 million in 2024, then fell by 4.7% to $17.9 million in 2025.
- Its Accounts Payables stands at $17.9 million for Q3 2025, versus $13.8 million for Q2 2025 and $16.3 million for Q1 2025.